Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Lillys Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Comprehensive Management of Cardiovascular Risk factors for adults with type 2 diabetes: a Scientific Statement from the American Heart Association
* Daily Value not established
There are also other practical reasons to prescribe these drugs in people with type 2 diabetes, because all three classes are associated with relatively low risk of hypoglycemic events, while patients treated with GLP-1RA and SGLT-2 inhibitors may also benefit from weight loss [11]
US$ 23.33
US$ 28.05
US$ 29.48
US$ 25.93
US$ 24.08
US$ 24.30
US$ 29.70
